(Q36641445)

15 August 2017

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer (English)

1 reference

15 August 2017

1 reference

1 reference

U Halm

1

1 reference

15 August 2017

T Schumann

2

1 reference

15 August 2017

I Schiefke

3

1 reference

15 August 2017

H Witzigmann

4

1 reference

15 August 2017

J Mössner

5

1 reference

15 August 2017

V Keim

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

82

1 reference

15 August 2017

5

1 reference

15 August 2017

1013-1016

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1035

15 August 2017

0 references

cites work

Gemcitabine--a safety review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Chemotherapy for pancreatic carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Chemotherapy of adenocarcinoma of the pancreas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Phase II study of gemcitabine in patients with advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Colorectal carcinoma antigens detected by hybridoma antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374423

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

20 September 2018

1 reference

12 December 2020

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

12 December 2020

Prognostic value of CA 19-9 serum course in pancreatic cancer

1 reference

12 December 2020

Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.1999.1035

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

10737382

1 reference